Application of Machine Learning Techniques to Predict Bone Metastasis in Patients with Prostate Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Steele CB, Li J, Huang B, Weir HK. Prostate cancer survival in the United States by race and stage (2001‐2009): findings from the concord‐2 study. Cancer. 2017;123:5160–5177. doi:10.1002/cncr.3102629205313
   PubMed Web of Science ®Google Scholar
• McDougall JA, Bansal A, Goulart BH, et al. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21(3):320. doi:10.1634/theoncologist.2015-032726865591
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–167. doi:10.1016/j.juro.2010.03.03420483155
   PubMed Web of Science ®Google Scholar
• Sanjaya I, Mochtar CA, Umbas R. Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans? Asian Pac J Cancer Prev. 2013;14(9):4973–4976. doi:10.7314/APJCP.2013.14.9.497324175761
   PubMedGoogle Scholar
• Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860–1867. doi:10.1002/cncr.2299117763372
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. CliNl Cancer Res. 2016;22(1):9–15. doi:10.1158/1078-0432.CCR-15-0820
   PubMed Web of Science ®Google Scholar
• Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med. 2017;58(8):1196–1200. doi:10.2967/jnumed.117.19102328663195
   PubMed Web of Science ®Google Scholar
• Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016;16(11):1177–1188. doi:10.1080/14737159.2016.124305727679869
   PubMed Web of Science ®Google Scholar
• Farooki A, Leung V, Tala H, Tuttle RM. Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 2012;97(7):2433–2439. doi:10.1210/jc.2012-116922564664
   PubMed Web of Science ®Google Scholar
• Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–589. doi:10.1001/jamasurg.2018.050129617544
   PubMed Web of Science ®Google Scholar
• Liu WC, Li ZQ, Luo ZW, Liao WJ, Liu ZL, Liu JM. Machine learning for the prediction of bone metastasis in patients with newly diagnosed thyroid cancer. Cancer Med. 2021;10(8):2802–2811. doi:10.1002/cam4.377633709570
   PubMed Web of Science ®Google Scholar
• Goecks J, Jalili V, Heiser LM, Gray JW. How machine learning will transform biomedicine. Cell. 2020;181(1):92–101. doi:10.1016/j.cell.2020.03.02232243801
   PubMed Web of Science ®Google Scholar
• Darcy AM, Louie AK, Roberts LW. Machine learning and the profession of medicine. JAMA. 2016;315(6):551–552. doi:10.1001/jama.2015.1842126864406
   PubMed Web of Science ®Google Scholar
• Oliphant TE. Python for scientific computing. Comput Sci Eng. 2007;9(3):10–20. doi:10.1109/MCSE.2007.58
   Web of Science ®Google Scholar
• Altmann A, Toloşi L, Sander O, Lengauer T. Permutation importance: a corrected feature importance measure. Bioinformatics. 2010;26(10):1340–1347. doi:10.1093/bioinformatics/btq13420385727
   PubMed Web of Science ®Google Scholar
• Chen T, He T, Benesty M, Khotilovich V, Tang Y, Cho H. Xgboost: extreme gradient boosting. R Package Version 04-2. 2015;1(4):1–4.
   Google Scholar
• Qi Y. Random forest for bioinformatics. In: Ensemble Machine Learning. Springer; 2012:307–323.
   Google Scholar
• Tang J, Deng C, Huang G-B. Extreme learning machine for multilayer perceptron. IEEE Trans Neural Netw Learn Syst. 2015;27(4):809–821. doi:10.1109/TNNLS.2015.242499525966483
   PubMed Web of Science ®Google Scholar
• Sperandei S. Understanding logistic regression analysis. Biochem Med. 2014;24(1):12–18. doi:10.11613/BM.2014.003
   PubMed Web of Science ®Google Scholar
• Myles AJ, Feudale RN, Liu Y, Woody NA, Brown SD. An introduction to decision tree modeling. J Chemom. 2004;18(6):275–285. doi:10.1002/cem.873
   Web of Science ®Google Scholar
• Rish I, editor. An empirical study of the naive Bayes classifier. In: IJCAI 2001 Workshop on Empirical Methods in Artificial Intelligence; 2001.
   Google Scholar
• Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. Bone Miner Res. 2018;33(12):2099–2113. doi:10.1002/jbmr.3618
   PubMed Web of Science ®Google Scholar
• Kuten J, Fahoum I, Savin Z, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61(4):527–532. doi:10.2967/jnumed.119.23418731562225
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A, Babich JW, Kratochwil C, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57(Supplement3):79S–89S. doi:10.2967/jnumed.115.17072027694178
   PubMed Web of Science ®Google Scholar
• Lenzo NP, Meyrick D, Turner JH. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics. 2018;8(1):16. doi:10.3390/diagnostics8010016
   Web of Science ®Google Scholar
• Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-generation machine learning for biological networks. Cell. 2018;173(7):1581–1592. doi:10.1016/j.cell.2018.05.01529887378
   PubMed Web of Science ®Google Scholar
• Zhu J, Zheng J, Li L, et al. Application of machine learning algorithms to Predict central lymph node metastasis in T1-T2, non-invasive, and clinically node negative papillary thyroid carcinoma. Front Med. 2021;8. doi:10.3389/fmed.2021.635771
   Web of Science ®Google Scholar
• Ogunleye A, Wang Q-G. XGBoost model for chronic kidney disease diagnosis. IEEE/ACM Trans Comput Biol Bioinform. 2019;17(6):2131–2140. doi:10.1109/TCBB.2019.2911071
   Web of Science ®Google Scholar
• Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1):S2–S11. doi:10.1016/j.juro.2012.11.01423234625
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN clinical practice guidelines in oncology. Prostate cancer V. 4; 2011. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed November 17, 2021.
   Google Scholar
• Guo X, Zhang C, Guo Q, et al. The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer. Cancer Manag Res. 2018;10:1639. doi:10.2147/CMAR.S16857929970963
   PubMed Web of Science ®Google Scholar
• Briganti A, Suardi N, Gallina A, et al. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3–11. doi:10.1016/j.ctrv.2013.07.00123896177
   PubMed Web of Science ®Google Scholar
• Chen S, Wang L, Qian K, et al. Establishing a prediction model for prostate cancer bone metastasis. Int J Biol Sci. 2019;15(1):208. doi:10.7150/ijbs.2753730662360
   PubMed Web of Science ®Google Scholar
• Stolzenbach LF, Rosiello G, Deuker M, et al. The impact of race and age on distribution of metastases in patients with prostate cancer. J Urol. 2020;204(5):962–968. doi:10.1097/JU.000000000000113132396050
   PubMed Web of Science ®Google Scholar
• Lu YJ, Duan WM. Establishment and validation of a novel predictive model to quantify the risk of bone metastasis in patients with prostate cancer. Transl Androl Urol. 2021;10(1):310–325. doi:10.21037/tau-20-113333532320
   PubMed Web of Science ®Google Scholar
• Wilczak W, Wittmer C, Clauditz T, et al. Marked prognostic impact of minimal lymphatic tumor spread in prostate cancer. Eur Urol. 2018;74(3):376–386. doi:10.1016/j.eururo.2018.05.03429908878
   PubMed Web of Science ®Google Scholar
• Battisti V, Maders LD, Bagatini MD, et al. Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: influence of Gleason score, treatment and bone metastasis. Biomed Pharmacother. 2013;67(3):203–208. doi:10.1016/j.biopha.2012.12.00423433854
   PubMed Web of Science ®Google Scholar
• Zaman MU, Fatima N, Sajjad Z. Metastasis on bone scan with low prostate specific antigen (≤ 20 ng/mL) and Gleason’s score (< 8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines. Asian Pac J Cancer Prev. 2011;12(6):1529–1532.22126493
   PubMedGoogle Scholar
• Vaarala MH, Hirvikoski P, Kauppila S, Paavonen TK. Identification of androgen-regulated genes in human prostate. Mol Med Rep. 2012;6(3):466–472. doi:10.3892/mmr.2012.95622735730
   PubMed Web of Science ®Google Scholar